Genoss Co., Ltd. (Korean: 제노스) - Korean Medical Device Innovation Leader

Company Overview (Updated April 2026)

Genoss Co., Ltd. (Korean: 제노스) is a medical device manufacturing company headquartered in Suwon, Gyeonggi-do, South Korea. Founded in February 2004, the company has grown from a bone graft material specialist into a comprehensive medical device manufacturer serving cardiovascular, orthopedic, dental, and aesthetic medicine markets.

Mission: To become one of the world's leading medical device manufacturers by investing over 20% of annual revenue into R&D and delivering innovative, high-quality healthcare products at affordable prices.

Corporate History and Development (2004-2026)

Early Years and Foundation (2004-2013)

- February 2004: Established as Genoss Co., Ltd. in Suwon, Korea

- January 2005: First product OSTEON bone graft material approved in South Korea

- May 2006: Achieved ISO 9001 and ISO 13485 certifications; obtained CE marking

- January 2007: OSTEON FDA approved; established Corporate R&D Center (Biomaterials Research Institute)

- September 2009: KGMP (Korea Good Manufacturing Practice) acquisition for medical device quality management

Expansion and Diversification (2012-2024)

- 2012: Bare metal coronary stent approved in South Korea; PTCA balloon catheter CE approved

- 2013: Lumbar pedicle screw and NC PTCA balloon catheter CE approved; expanded into spinal devices

- 2016: NC PTCA Balloon Catheter approved in china (NMPA Registration No. 国械注进20163773262)

- 2019: Monalisa Lidocaine Filler (hyaluronic acid dermal filler) approved in China (国械注进20193130627)

- 2025-2026: Established corporate office in China and manufacturing facility in Vietnam to supply Asian markets

Core Product Portfolio

Cardiovascular Devices

GENOSS™ DES (Drug-Eluting Coronary Stent System):

- First Korean sirolimus-eluting stent on the market

- 70μm ultra-thin strut design using cobalt-chromium alloy for high strength and biocompatibility

- Asymmetric polymer coating to optimize drug release and reduce restenosis risk

- Polymer releases ~70% of drug within 30 days; fully absorbable within 9 months

GENOSS™ DCB (Paclitaxel-Coated PTCA Balloon Catheter):

- Uniform drug coating for effective drug delivery and durability

- Suppresses neointimal hyperplasia to maintain long-term vessel patency

- China NMPA Approval: January 2026 (国械注进20263030008)

GENOSS™ PTCA Balloon Catheter:

- High-strength materials withstand high pressure for effective vessel expansion

- High rewrap performance and soft tapered tip for smooth navigation

Extractor™ Aspiration Catheter:

- Large lumen and enhanced suction power for efficient thrombus removal

- Hydrophilic coating for smooth navigation and operational ease

Orthopedic and Dental Biomaterials

OSTEON™ Bone Graft Substitutes:

- First product approved in 2005; OSTEON II FDA approved in 2012

- Synthetic bone graft materials for orthopedic and dental applications

- OSTEON III and collagen variants available

GENOSS™ Collagen Membrane:

- Resorbable dental barrier membrane for guided tissue regeneration

- FDA 510(k) cleared; CE marked for dental implant procedures

Zirconia Ceramic Blocks:

- rainbow™ Shine T and rainbow™ High Shine pre-sintered zirconia blocks for CAD/CAM dental prosthetics

- Y-TZP (Yttria-Stabilized Tetragonal Zirconia PolyCrystal) material

- FDA 510(k) approved (2009) for dental core manufacturing

- Available in multiple shades (A0, A1, A2, A3) and heights (12mm-24mm)

Aesthetic Medicine

Monalisa™ Dermal Fillers:

- Hyaluronic acid-based fillers including Monalisa Lidocaine Filler with pain-reducing lidocaine

- Known for high quality at competitive prices due to in-house syringe and needle manufacturing

- Products: MPF03H, MPF05H, MPF10H variants for mid-to-deep dermal injection

- CE, KFDA, and FDA certified

Bright Serum & Bright Essence (Launched March 2026):

- PDRN (Polydeoxyribonucleotide) and hyaluronic acid skincare products

- Bright Serum: 20,000ppm PDRN + 5,000ppm hyaluronic acid; clinically proven 36.1% moisture increase after 2 weeks

- Bright Essence: 5,000ppm PDRN + 1,000ppm hyaluronic acid + 50,000ppm Centella asiatica extract

Global Presence and Markets

Export Markets:

- Products exported to over 40 countries including Germany, Italy, Russia, Mexico, Japan, China, Saudi Arabia

- Certified in major markets: Europe (CE), USA (FDA), China (NMPA)

International Facilities:

- China: Established corporate office to serve Chinese market

- Vietnam: Manufacturing facility to supply Vietnamese and broader Asian markets

Key Trade Shows:

- Regular participant at KIMES (Korea International Medical & Hospital Equipment Show); showcased cardiovascular devices at KIMES 2025

Research and Development

- R&D Investment: Over 20% of annual revenue invested in R&D

- R&D Center: Established Corporate R&D Center (Biomaterials Research Institute) in 2006

- Clinical Trials: GENOSS DES clinical trial comparing against Xience everolimus-eluting stent (Abbott Vascular)

- Patent Portfolio: Multiple patents including drug-coated balloon catheters, dental implant drilling drivers, and multi-drilling guide devices

Competitive Market Position

Genoss is recognized as a key player in multiple medical device markets:

- Zirconia Ceramic Blocks Market: Listed among top companies globally alongside VITA Zahnfabrik, Dentium, 3M Deutschland

- Periodontal Guided Tissue Regeneration Membranes: Market presence noted in global market reports

- Dermal Fillers Market: Listed as major player in global market reports alongside Allergan, Galderma, Merz Pharma

- Oral Cavity Repair Membrane Market: Recognized competitor alongside Geistlich, Keystone Dental

- Soft Tissue Repair Materials: Listed among key companies

Leadership and Governance

Executive Leadership

Chief Executive Officer: Sung Min Chung (정성민)

- Led company participation at KIMES 2025

- Listed as inventor on multiple patents including drug-coated balloon catheter technology

Management Team:

- In Kwon Jung

- Nak Jung Yong

- Eugene Joeng (EC21 contact)

Financial Performance (2024)

- Annual Revenue: Approximately $24.5 million USD (24.47 million)

- Employees: 182 (as of 2024)

- Corporate Family: 2 companies in the Genoss corporate family

Company Information

Corporate Details

Legal Name: Genoss Co., Ltd. / Genoss Company, Limited / 吉诺斯株式会社

Founded: February 2004

Headquarters: 1F, Gyeonggi R&DB Center /226, 2F, GSBC, 105 Gwanggyo-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, Korea

Phone: +82-31-888-5100

Fax: +82-31-888-5105

Status: Private company

Industry: Medical Device Manufacturing - Cardiovascular, Orthopedic, Dental, Aesthetic Medicine

Certifications: ISO 9001, ISO 13485, KGMP, CE, FDA, KFDA, NMPA (China)

Contact Information

Website: www.genoss.com, genoss.en.ec21.com

Email: ykkim@implantium.com (QA), dicksong@fdi.com (related to US operations)

Keywords: Genoss Co Ltd, 제노스, Sung Min Chung, drug-eluting stent, DES, DCB, balloon catheter, Monalisa filler, hyaluronic acid, zirconia block, rainbow block, collagen membrane, OSTEON, bone graft, dental implant, cardiovascular, orthopedic, Suwon Korea, KIMES, PDRN, Bright Serum, 2004 founded, NMPA approval